Abstracts tagged "treatment"

Abstract Number: 1874 • 2019 ACR/ARP Annual Meeting
Extensive Modeling-Based Bone Formation After 2 Months of Romosozumab Treatment: Results from the FRAME Clinical Trial
Erik Eriksen¹, Roland Chapurlat ², Rogely Boyce ³, Jacques Brown ⁴, Stéphane Horlait ⁵, Cesar Libanati ⁶, Yifei Shi ³, Rachel Wagman ³ and Pascale Chavassieux ², ¹Department of Clinical Endocrinology, Oslo University Hospital and Institute of Clinical Medicine Oslo University, Oslo, Norway, ²INSERM UMR 1033, Université de Lyon, Lyon, France, ³Amgen Inc., Thousand Oaks, CA, ⁴CHU de Quebec Research Centre and Laval University, Quebec, QC, Canada, ⁵Amgen Inc., Boulogne Billancourt, France, ⁶UCB Pharma, Brussels, Belgium
Background/Purpose: The bone-forming agent romosozumab (Romo) is a monoclonal antibody that binds to/inhibits sclerostin, leading to increased bone formation and decreased bone resorption. The highest…
Abstract Number: 2871 • 2019 ACR/ARP Annual Meeting
Advances in Treatment of Rheumatoid Arthritis: ACPA-positive Patients Benefited More Than ACPA-negative Patients; 25 Year Results of a Longitudinal Cohort Study
Xanthe ME Matthijssen¹, Ellis Niemantsverdriet ², Thomas Huizinga ² and Annette van der Helm-van Mil ³, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³LUMC, Leiden, Zuid-Holland, Netherlands
Background/Purpose: The last 25 years, treatment of rheumatoid arthritis (RA) has changed considerably. Although clinically relevant joint damage has become infrequent, it is less established…
Abstract Number: 250 • 2019 ACR/ARP Annual Meeting
Treatment Patterns, Dose Change, and Treatment Discontinuation in RA Patients Switching from First Biologic DMARD to Another Treatment in the US
Robin Dore¹, Jenya Antonova ², Chakkarin Burudpakdee ³, Lawrence Chang ², Jing He ⁴ and Mark Genovese ⁵, ¹Private practice, Tustin, CA, ²Gilead Sciences, Foster City, CA, ³IQVIA, Falls Church, VA, ⁴IQVIA, Plymouth meeting, PA, ⁵Stanford University, Stanford, CA
Background/Purpose: For RA patients not meeting their treat-to-target goals despite treatment with their first biologic (b)DMARD, ACR guidelines recommend switching to a different bDMARD or…
Abstract Number: 543 • 2019 ACR/ARP Annual Meeting
Cytokine Signaling Pathways Inhibited by Different Biologics in Rheumatoid Arthritis Patients
Sergio Duran-Barragan¹, Efrain Chavarria-Avila ¹, Marisol Esesarte-Rodriguez ¹, Rosal Valenzuela-Marrufo ¹, Karla Arrona-Ríos ¹, Jorge Aguilar-Arreola ¹, Oscar Pizano Martínez ¹ and Monica Vazquez-del Mercado ¹, ¹Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
Background/Purpose: Different types of cells play pathogenic roles in Rheumatoid Arthritis (RA). The immunogenetics of RA suggests a key role of aberrant pathways of T…
Abstract Number: 1380 • 2019 ACR/ARP Annual Meeting
Patient Characteristics, Treatment Patterns, and Treatment Persistency in Biologic DMARD-Experienced Rheumatoid Arthritis Patients in a US RA Registry
Robin Dore¹, Jenya Antonova ², Leslie Harrold ³, Lawrence Chang ², Emily Scherer ⁴, Angel Cronin ⁵, Kelechi Emeanuru ⁵ and Joel Kremer ⁶, ¹Private practice, Tustin, CA, ²Gilead Sciences, Foster City, CA, ³Corrona, LLC and University of Massachusetts Medical School, Worcester, MA, ⁴Corrona, LLC, Cambridge, MA, ⁵Corrona, LLC, Waltham, MA, ⁶Albany Medical College and The Center for Rheumatology; Corrona, LLC, Albany, NY
Background/Purpose: Multiple treatment options are available for patients with RA. ACR guidelines recommend initiating treatment with a conventional synthetic DMARD (csDMARD). If a patient fails…
Abstract Number: 1945 • 2019 ACR/ARP Annual Meeting
Polymorphisms in Genes Involved in Methotrexate Pathway: Predictor of Response to Methotrexate Therapy in Indian Rheumatoid Arthritis Patients
Ankita Singh¹, Harikrishnan Nair ², Vikas Gupta ², Pradeepta Sekhar ², Ramnath Misra ³ and Amita Aggarwal ⁴, ¹Sanjay Gandhi Post Graduate institute of medical science, Lucknow, India, Lucknow, Uttar Pradesh, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ³Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, Uttar Pradesh, India, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Methotrexate (MTX) is first line therapy to treat rheumatoid arthritis (RA) patients. However, the response is variable with 50-60% showing response and this variability…
Abstract Number: 402 • 2019 ACR/ARP Annual Meeting
Chronic Disease Course and IVIg-dependance in Long-term Follow-up of Anti-HMGCR Immune-mediated Necrotizing Myopathy
Océane Landon-Cardinal¹, Kuberaka Mariampillai ², Céline Anquetil ³, Aude Rigolet ², Baptiste Hervier ⁴, Nicolas Champtiaux ², Olivier Benveniste ³ and Yves Allenbach ³, ¹Centre Hospitalier de l'Université de Montréal, Montréal, Canada, ²Pitié-Salpêtrière University Hospital, Paris, France, ³Sorbonne Université, Paris, France, ⁴Hopital Pitie-Salpetriere, Paris, France
Background/Purpose: Anti-HMGCR antibodies have been associated with a severe form of immune-mediated necrotizing myopathy (IMNM) with a poor muscle strength recovery and early muscle damage.…
Abstract Number: 550 • 2019 ACR/ARP Annual Meeting
Rheumatoid Arthritis Treatment with Filgotinib: Week 156 Safety and Efficacy Data from a Phase 2b Open-Label Extension Study
Arthur Kavanaugh¹, Rene Westhovens ², Kevin Winthrop ³, Susan Lee ⁴, Joy Greer ⁴, Adam DeZure ⁴, Di An ⁴, Lei Ye ⁴, John Sundy ⁴, Robin Besuyen ⁵, Luc Meuleners ⁵, Rieke Alten ⁶ and Mark Genovese ⁷, ¹University of California, San Diego School of Medicine, La Jolla, CA, ²University Hospitals, Leuven, Belgium, ³Oregon Health and Science University, Portland, OR, ⁴Gilead Sciences, Inc., Foster City, CA, ⁵Galapagos NV, Mechelen, Belgium, ⁶Schlosspark-Klinik University Medicine, Berlin, Germany, ⁷Stanford University, Stanford, CA
Background/Purpose: Filgotinib (FIL) is an oral selective Janus kinase (JAK1) inhibitor. In studies to date, FIL has been shown to be effective and safe in…
Abstract Number: 1385 • 2019 ACR/ARP Annual Meeting
Discontinuation of Oral Glucocorticoid After Initiation of Biological DMARDs Due to a Higher Dose of Methotrexate; A Retrospective Observational Study Based on Data from a Japanese Multicenter Registry Study
Mochihito Suzuki¹, Toshihisa Kojima ², Nobunori Takahashi ², Shuji Asai ² and Naoki Ishiguro ², ¹Nagoya University Graduate School of Medicine, Nagoya, Japan, ²Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose: In the treatment of rheumatoid arthritis (RA), glucocorticoid that provide anti-inflammatory effects is an important drug. We recommend discontinuing of glucocorticoid as soon as…
Abstract Number: 2012 • 2019 ACR/ARP Annual Meeting
A Composite IFN-Based Signature Is Associated with a Filgotinib-Specific Clinical Response in bDMARD-Experienced Rheumatoid Arthritis Patients
Peter Taylor¹, Bryan Downie ², Emon Elboudwarej ³, Rachael Hawtin ³, Amer M. Mirza ³ and Jinfeng Liu ³, ¹University of Oxford, Oxford, United Kingdom, ²Gilead Sciences, Inc., Foster Citty, CA, ³Gilead Sciences, Inc., Foster City, CA
Background/Purpose: Filgotinib (FIL), an oral, selective, Janus Kinase 1 (JAK1) inhibitor was effective in Phase 3 studies of active RA in patients (pts) with inadequate…
Abstract Number: 473 • 2019 ACR/ARP Annual Meeting
RA Presents in Disease Patterns Impacting Treatment Response
Kathryne Marks¹, Dana Symons ², Cynthia Crowson ³, Pamela Sinicrope ⁴ and Kelly O'Neill ⁵, ¹Rosalind Franklin University of Medicine and Science, Gurnee, IL, ²Rheumatoid Patient Foundation, Inc., Rockford, MI, ³Mayo Clinic Rochester, Rochester, ⁴Mayo Clinic, Rochester, MN, ⁵Rheumatoid Patient Foundation, Inc., Winter Springs, FL
Background/Purpose: Despite significant research on rheumatoid arthritis (RA), disease courses have not been clearly described. Like systemic lupus erythematosus and multiple sclerosis, RA displays a…
Abstract Number: 557 • 2019 ACR/ARP Annual Meeting
Comparing Symptoms, Treatments Patterns, and Quality of Life of Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis Patients: Findings from a US Survey
Theresa Hunter¹, David Sandoval ², Nicola Booth ³, Elizabeth Holdsworth ⁴ and Atul Deodhar ⁵, ¹Eli Lilly and Company, Indianapolis, ²Eli Lilly and Company, Indianapolis, IN, ³Adelphi Real World, Bollington, United Kingdom, ⁴Adelphi Real World, Manchester, England, United Kingdom, ⁵Oregon Health & Science University, Portland, OR
Background/Purpose: To better understand the symptoms, clinical characteristics, treatment patterns, and quality of life (QoL), of non-radiographic axial spondyloarthritis (nr-axSpA) patients and how they compare…
Abstract Number: 1400 • 2019 ACR/ARP Annual Meeting
Real Life Retention of Tofacitinib in Patients with Rheumatoid Arthritis
Aniela Croiteru ¹, Merav Lidar ², Tatiana Reitblat³, Devy Zisman ⁴, Alexandra Balbir-Gurman ⁵, Tanya Meshiach ⁵, Ronit Almog ⁵ and Ori Elkayam ⁶, ¹Tel Aviv medical center, Tel Aviv, Israel, ²Sheba Medical Center, Ramat Gan, Israel, ³Barzilai Medical Center, Ashkelon, Israel, ⁴Carmel Hospital and Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel, Haifa, Israel, ⁵Rambam Medical Center, Haifa, Israel, ⁶Rheumatology Department, Tel Aviv Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Israel., Tel Aviv, Israel
Background/Purpose: Tofacitinib (Xeljanz) is an approved treatment for Rheumatoid Arthritis (RA) but data on its use in “real life” are limited. We sought to analyze…
Abstract Number: 2162 • 2019 ACR/ARP Annual Meeting
Characteristics of Patients with Rheumatoid Arthritis Undergoing Primary Total Joint Replacement: A 14-year Trend Analysis (2004-2017)
Shuji Asai¹, Toshihisa Kojima ¹, Nobunori Takahashi ¹ and Naoki Ishiguro ¹, ¹Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
Background/Purpose: Total joint replacement (TJR) is performed when severe large joint destruction causes functional disability in patients with rheumatoid arthritis (RA). Biologics were approved in…
Abstract Number: 504 • 2019 ACR/ARP Annual Meeting
A Subgroup Analysis of the Efficacy of Filgotinib in Demographic and Clinical Subgroups of Patients with Refractory Rheumatoid Arthritis
Kenneth Kalunian¹, Mark Genovese ², Jacques-Eric Gottenberg ³, Beatrix Bartok ⁴, Alena Pechonkina ⁴, Ying Guo ⁴, Chantal Tasset ⁵, John Sundy ⁴, Kurt de Vlam ⁶, David Walker ⁷ and Tsutomu Takeuchi ⁸, ¹Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ²Stanford University, Stanford, CA, ³Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁴Gilead Sciences, Inc., Foster City, CA, ⁵Galapagos NV, Mechelen, Belgium, ⁶Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium, ⁷Northumbria Healthcare, Northumbria, United Kingdom, ⁸Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: RA patients who have failed biologic DMARDs represent an unmet medical need. We explored the impact of baseline demographics and clinical characteristics on filgotinib…

« Previous Page
1
…
3
4
5
6
7
…
22
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].